Their findings support the use of pharmaceutical medicines like sulforaphane to target this pathway and prevent COPD exacerbations caused by bacterial infection by highlighting the significance of Nrf2 and its downstream target MARCO in enhancing antibacterial defences. This evidence concerns the gene NFE2L2 and bacterial infectious disease.